CoChat

Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials

Open access
Selak, Vanessa, Webster, Ruth, Stepien, Sandrine, Bullen, Chris, Patel, Anushka, Thom, Simon, Arroll, Bruce, Bots, Michiel L, Brown, Alex, Crengle, Sue, Dorairaj, Prabhakaran, Elley, C Raina, Grobbee, Diederick E, Harwood, Matire, Hillis, Graham S, Laba, Tracey-Lea, Neal, Bruce, Peiris, David, Rafter, Natasha, Reid, Christopher, Stanton, Alice, Tonkin, Andrew, Usherwood, Tim, Wadham, Angela, Rodgers, Anthony · 2019 · Heart
Cited by 62

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Objective: The aim of this study was to determine the effect of polypill-based care on the achievement of 2016 European Society of Cardiology (ESC) guideline targets for blood pressure (BP), low-density lipoprotein (LDL) cholesterol and antiplatelet therapy. Methods: We conducted an individual participant data meta-analysis of three randomised clinical trials that compared a strategy using a polypill containing aspirin, statin and antihypertensive therapy with usual care in patients with a prior cardiovascular disease (CVD) event or who were at high risk of their first event. Overall, the trials included 3140 patients from Australia, England, India, Ireland, the Netherlands and New Zealand (75% male, mean age 62 years and 76% with a prior CVD event). The primary outcome for this study was the proportion of people achieving ESC guideline targets for BP, LDL and antiplatelet therapy. Results: Those randomised to polypill-based care were more likely than those receiving usual care to achieve recommended targets for BP (62% vs 58%, risk ratio (RR) 1.08, 95% CI 1.02 to 1.15), LDL (39% vs 34%, RR 1.13, 95% CI 1.02 to 1.25) and all three targets for BP, LDL and adherence to antiplatelet therapy (the latter only applicable to those with a prior CVD event) simultaneously (24% vs 19%, RR 1.27, 95% CI 1.10 to 1.47) at 12 months. There was no difference between groups in antiplatelet adherence (96% vs 96%, RR 1.00, 95% CI 0.98 to 1.01). There was heterogeneity by baseline treatment intensity such that treatment effects increased with the fewer the number of treatments being taken at baseline: for patients taking 3, 2 and 0–1 treatment modalities the RRs for reaching all three guideline goals simultaneously were 1.10 (95% CI 0.94 to 1.30, 22% vs 20%), 1.62 (95% CI 1.09 to 2.42, 27% vs 17%) and 3.07 (95% CI 1.77 to 5.33, 35% vs 11%), respectively. Conclusions: Polypill-based therapy significantly improved the achievement of all three ESC targets for BP, LDL and antiplatelet therapy compared with usual care, particularly among those undertreated at baseline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/heartjnl-2018-313108

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 62

Metadata

Authors
Selak, V., Webster, R., Stepien, S., Bullen, C., Patel, A., Thom, S., Arroll, B., Bots, M. L., Brown, A., Crengle, S., Dorairaj, P., Elley, C. R., Grobbee, D. E., Harwood, M., Hillis, G. S., Laba, T.-L., Neal, B., Peiris, D., Rafter, N., Reid, C., Stanton, A., Tonkin, A., Usherwood, T., Wadham, A., & Rodgers, A.
Venue
Heart
Publisher
BMJ
Published
2018-06-28
Volume
105
Issue
1
Pages
42-48
ISSN
  • 1355-6037 (ISSN-L)
  • 1468-201X
OpenAlex
W2809717331
Cited by
62
References
11
FWCI
1.78
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. https://app.cochat.ai/papers/10.1136/heartjnl-2018-313108
The paper
Selak, V., Webster, R., Stepien, S., Bullen, C., Patel, A., Thom, S., Arroll, B., Bots, M. L., Brown, A., Crengle, S., Dorairaj, P., Elley, C. R., Grobbee, D. E., Harwood, M., Hillis, G. S., Laba, T.-L., Neal, B., Peiris, D., Rafter, N., . . . Rodgers, A. (2019). Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart. https://doi.org/10.1136/heartjnl-2018-313108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.